OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2022-12-31-accounts

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

Charity Registration No. 1183890 (England and Wales) Charity Registration No. SC049802 (Scotland) Company Registration No. 11911752 (England and Wales)

LEUKAEMIA CARE

ANNUAL REPORT AND CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

www.leukaemiacare.org.uk

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

LEGAL AND ADMINISTRATIVE INFORMATION

Patrons Lady Penny Mountbatten Beverley Warboys Trustees Mr Christopher R G Matthews-Maxwell (Chair) Mrs W J Davies (Treasurer) Dr Emmanouil Nikolousis Ms E Wilson (Vice Chair) Ms Kate Stallard Mr Robert Heppell Mr Dharmesh Mehta Professor Mhairi Copland (Appointed 2 February 2022) Ms Carina Patterson Helen Knight (Appointed 4 May 2022) Dr Sarah Smith (Appointed 2 February 2022) President Dr Richard Taylor Vice Presidents Ms Sue Merchant Mr Roland Maturi Professor Claire Harrison Dr Robert Marcus Professor Andrew Pettitt Dr Noel E M Harker Ms Sheila Hegarty Mr Jason Eliadis Mr C.R.G. Matthews-Maxwell Mr Peter Mondon Mr Anthony Gavin Mr Albert Podesta Senior Management Team Chief Executive Officer Zack Pemberton-Whiteley Chief Operating Officer and Deputy CEO Monica Izmajlowicz Communications and Fundraising Director Nicole Scully Medical Advisory Panels As descibed in the Trustees' Report Secretary Monica Izmajlowicz Charity number (England and Wales) 1183890 Charity number (Scotland) SC049802 Company number 11911752 Website www.leukaemiacare.org.uk

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

LEGAL AND ADMINISTRATIVE INFORMATION

Registered office One Birch Court
Blackpole East
Worcester
WR3 8SG
Auditor Kendall Wadley LLP
Granta Lodge
71 Graham Road
Malvern
Worcestershire
WR14 2JS
Bankers Barclays Bank Plc
54 High Street
Worcester
WR1 2QQ
Solicitors Harrison Clark Rickerbys
5 Deansway
Worcester
WR1 2JG
Investment advisors Cardale Asset Management
2 Greengate
Cardale Park
Harrogate
HG3 1GY
CCLA
Senator house
85 Queen Victoria Street
London
EC4V 4ET
Brewin Dolphin
12 Smithfield Street
London
EC1A 9BD

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

CONTENTS

Page
A word from our Chairman and CEO 1
Trustees' report 2 - 28
Statement of trustees' responsibilities 29
Independent auditor's report 30- 32
Statement of consolidated financial activities 33
Statement of financial activities - charity 34
Consolidated Balance sheet 35- 36
Charity Balance sheet 37- 38
Statement of cash flows 39
Notes to the financial statements 40- 61

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

A word from our Chairman and CEO FOR THE YEAR ENDED 31 DECEMBER 2022

2022 was a year of change at Leukaemia Care – including a new long-term strategy, with a fresh look at our vision, mission, and long-term goals and the way we operate after the challenges of the pandemic. Our new strategy focuses on “The future we will create together” setting out our vision and goals to 2030. Alongside this we implemented an ambitious operational plan including significant investment from reserves to ensure we are on the path to delivering our long-term goals.

A key part of the plan is to diversify and grow our income to allow us to deliver new services and expand existing ones to reach more people. To do this, we expanded our fundraising team bringing in expertise in areas such as grants and trusts, while increasing resources in existing fundraising streams.

Planning started on Leukaemia Care’s first public art trail “Unicornfest”, with a trail of 60 sponsored unicorn statues throughout Bristol throughout the Summer of 2023 raising both awareness and funds for Leukaemia Care. Each sculpture is painted by a local artist, which will then be auctioned to raise money for the charity.

Other exciting developments include the launch of World Gaming Day on the 22 October – a new initiative from Leukaemia Care encouraging supporters to gather with friends to play games and raise money for charity.

2022 will also go down on record as the year Leukaemia Care raised over £2 million for the first time! This represents our best year ever and a 59% growth on income from 2021. We ended the year with income up on budget, and contrary to expectations of a significant deficit we ended up with a surplus of approximately £95k. With this improvement in our financial position, we will work to invest further from reserves for the long-term benefit of the charity.

However, 2022 was not without its challenges. Recruitment delays across fundraising until late in the year put pressure on our staffing team to deliver on an ambitious plan which makes many of these achievements even more significant and mean we will start 2023 on the front foot.

Other significant achievements to take note of include growth in the number of new people accessing our services, successful partnerships with other charities including on the Spot Leukaemia campaign, providing additional financial support for the Cost of Living crisis through our financial grants and oversubscribed welfare service, widespread press coverage of Leukaemia Care and the people we support, and increasing our reach to ensure more people are aware of us and the ways we can provide support.

The quotes and testimonials within this report speak to the impact we are making to the lives of people affected by leukaemia, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). It is difficult not to be moved and we invite anyone to get involved and become part of this vibrant community of people working to improve the lives of people with blood cancer – we are, after all, Your Blood Cancer charity.

With warm wishes

Chris Matthews-Maxwell (Chair) and Zack Pemberton-Whiteley (CEO)

Date: 21 June 2023

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 DECEMBER 2022

The trustees present their annual report and financial statements for the year ended 31 December 2022.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charitable group's memorandum & articles of association, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).

Objectives and activities About us

Leukaemia Care is the UK’s leading leukaemia charity. For over 50 years, we have been dedicated to ensuring that everyone affected receives the best possible diagnosis, information, advice, treatment and support.

We are here for everyone affected by leukaemia and related blood cancer types – such as myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

We believe in improving lives and being a force for change. To do this, we have to challenge the status quo and do things differently.

Purpose

The charity’s objects are set out in its articles of association:

  1. The relief of sickness and the promotion and protection of good health among persons suffering from Leukaemia and allied blood disorders.

  2. The relief of need among families, carers and friends of persons suffering from leukaemia and allied blood disorders, and in particular those contemplating or suffering bereavement or who must contemplate the prospect of treatment where those needs are attributable to the affliction of leukaemia and allied blood disorders.

Our vision - our long term ideal

A future where everyone affected by leukaemia, MDS and MPN gets the best possible diagnosis, information, advice, treatment and support.

Our mission - What we are doing to make that vision a reality

We exist to improve the lives of everyone affected by leukaemia, MDS and MPN.

We provide information, advice and support for anyone affected, this includes patients and their friends and families too. We raise awareness of the issues impacting people affected by leukaemia, MDS and MPN, and campaign to fix them. We are driving early diagnosis, raising public awareness, improving services, and ensuring access to effective treatments.

But most importantly, we bring people together and unite them behind our common goal. Together, we will create the future we all believe in.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Our values - What do we stand for?

Leukaemia Care’s values are at the heart of everything we do. They describe our approach to our work. They drive our thinking, our behaviours and our actions.

Mission based

We have a clear mission. We exist to improve the lives of people affected by leukaemia, MDS and MPN. We believe in doing the right thing. If it is not in the best interests of people affected by our mission, we will not do it. It is that simple. No ifs, no buts, no exceptions.

Collaborative

We are passionate about all forms of collaboration, especially with other charities. Our mission is bigger than Leukaemia Care. We know that working on our own will delay the day when everyone affected by leukaemia, MDS and MPN gets the best possible diagnosis, information, advice, treatment and support. That is why it is so important that we work in partnership with individual charities, charity coalitions, healthcare professionals and a wide range of other stakeholders to improve the lives of people affected.

Caring

It is in our name, and it is in our nature. We care deeply about every single person affected by leukaemia, MDS and MPN. We are on your side and always will be. This helps us deliver high quality support, but also underpins all other parts of the charity. We care about the people who dedicate their time to our mission – whether that is our colleagues, volunteers, supporters or fundraisers. We are a community united by a common mission and we care about each other.

Evidence based

We listen to and understand the experiences of people affected by leukaemia, MDS and MPN. We use the evidence we gather to adapt, improve our services and to focus our campaigns for change. We also work with healthcare professionals – including haematologists, nurses and GPs – to make sure we are rooted in the latest science.

Aspirational

We have ambitious goals and we set ourselves high standards to achieve them. We believe that everyone affected by leukaemia, MDS and MPN should get the best possible diagnosis, information, advice, treatment and support. Every day 44 people are diagnosed with leukaemia, MDS or MPN, we can’t afford to wait. To achieve this change we must be innovators, problem solvers, challengers to the status quo and each and every one of us must go above and beyond, every single day.

Our values are key to everything we do. But we all make mistakes. If you see us acting in a way that you feel is not consistent with our values – please let us know!

Why our work is important

To paint a picture of the scale of the issue across the UK:

• Every year 6,000 people in the UK will be diagnosed with conditions that may develop into leukaemia, including myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Our Strategic Goals

We exist to improve the lives of everyone affected by leukaemia, MDS and MPN. Over the last 50 years, we have come a long way, but there is more to be done.

We are committed to creating a future where everyone affected by leukaemia, MDS and MPN gets the best possible diagnosis, information, advice, treatment and support.

That will not happen overnight. But we are closer than ever before, and we are working to create that future every single day.

Our organisational strategy focuses on the future we believe we can create and sets five clear goals for the work we will be doing until 2030 to make this a reality sooner:

  1. Improving diagnosis – through awareness and early detection.

  2. Ensuring everyone receives high quality information, advice and support.

  3. Tackling issues that impact people’s lives.

  4. Advancing treatment and care.

5. Creating a narrative to better reflect the reality people experience. But we need your help. If you believe in the future we are trying to create and want to help us get there faster, please get involved.

For more information on our five goals, please visit our website www.leukaemiacare.org.uk

Public benefit

Our work delivers public benefit by providing information, advice and support to anyone affected by a leukaemia diagnosis; patients, family members, friends as well as employers and schools looking for advice on how best to support employees and students. This information and support helps people to live better with their leukaemia by reducing the isolation that can come with a blood cancer diagnosis, clarity on their treatment options and improving quality of life with strategies to reduce the impact of the side effects of treatment.

Our '#SpotLeukaemia' campaign reaches a wider audience equipping people with the awareness of the common signs and symptoms of leukaemia. This empowers them to speak with their GP if they have any concerns and increases the likelihood of earlier diagnosis and effective treatment.

Our GP training raises awareness of the signs and symptoms of leukaemia among GPs and other key healthcare professionals increasing the likelihood of earlier diagnosis and effective treatment. Our nurse training provides much needed free training on aspects of caring for blood cancer patients thus enhancing their care.

Grant making by Leukaemia Care

Leukaemia Care has four grant making streams: the Financial Hardship Fund (now the Cost of Living with Leukaemia Fund), the Exceptional Hardship Fund, the Leukaemia Counselling Fund, and the CAR-T Away from Home Service (launched in 2022). These contribute towards addressing the recommendations made in our Living with leukaemia reports which inform our strategic aims.

Financial Hardship Fund (now the Cost of Living with Leukaemia Fund)

This fund provides grants of up to £200 for essential living costs to patients and their families affected by leukaemia, myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPN). There is no closing date, awards are distributed on a first-come, first-served basis until the fund is depleted each month. In 2022, we collaborated with Leukaemia UK, who provided a £20,000 grant to enable an additional 100 families to access this support.

The Financial Hardship Fund ran out in September, but we continued to register interest from people who would like to apply when further funding became available. Demand for the Fund was amplified with the UK’s recent cost of living crisis. Compared with 2021, 2022 has seen a 4-fold increase in applications to the fund. Demand for the service increased throughout the year from 37 per month in Q2 to 64 per month in Q3.

In December, we launched a short-term “Cost of Living with Leukaemia Fund” in partnership with Leukaemia UK who provided a £27,000 grant to co-fund the project, to help families affected by leukaemia, MDS and MPN get through the winter. Due to high demand, this was a £100 grant to eligible applicants rather than the usual £200. Our intention is to rename the Financial Hardship Fund going forward as the “Cost of Living with Leukaemia Fund”.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Exceptional Hardship Fund

Applicants who have received the Financial Hardship Fund of £200 within the year and are assessed as experiencing exceptional hardship are considered for an additional grant of up to £1,000. They are likely to be facing multiple challenges alongside a leukaemia diagnosis such as no recourse to public funds, homelessness or poor housing, significant mental health issues, care for a disabled dependant (adult and/or child) etc.

The Counselling Fund

We are committed to providing patients and their families with emotional and psychological support through their blood cancer diagnosis. To provide patients with a diagnosis of leukaemia, MDS or MPNs or a parent, sibling, child or spouse of a patient with a maximum of up to six sessions of counselling with a maximum award of £400. Counsellors must be registered with the British Association of Counselling and Psychotherapy (BACP), or the UK Council of Psychotherapy (UKCP). The fund opens at the beginning of each year and awards are distributed on a first-come, first-served basis until the fund is depleted for the year.

CAR-T Away from Home Service

CAR-T (Chimeric Antigen Receptor) t-cell therapy is a type of treatment for leukaemia that has revolutionized the way leukaemia is treated. It was first approved for B cell acute lymphoblastic leukaemia (ALL) but is expected to change the way other forms of leukaemia patients are treated in the future.

The way the therapy is delivered means that patients often have long periods of waiting and spending time near to hospital to receive the treatment.

There are a limited number of specialist hospitals currently able to deliver CAR-T therapy in England, Wales and Northern Ireland. As a result, patients may need to travel to a different part of the country to receive treatment and need accommodation nearby. This can cost a lot of money directly or stop the person from being able to earn an income in this time.

Leukaemia Care believes that financial circumstances should never prevent someone from accessing the treatment they need. We have set up this project with our partners, Dalata Hotels Group, to prevent this from happening to as many patients as possible.

People can apply for accommodation, grant funding or both with one grant per family. This grant is only open to those currently going through CAR-T therapy and people can apply as soon as they become aware that CAR-T is recommended as a treatment for them. The fund does not have a closing date and funds are allocated on a first come first served basis until the fund is depleted.

Thanks to our hotel partner Dalata, we can offer free accommodation in one double or twin room per family per stay for up to 30 days. This is booked and arranged by Leukaemia Care and we must know the dates in advance. This cannot be exchanged for money, vouchers, or another hotel.

We also pay up to £500 in a cash grant to help with other expenses related to having CAR-T therapy. This could include, but is not limited to travel expenses, increased food costs while away from home etc.

Achievements and performance

A new long-term strategy is launched

The pandemic accelerated our long-term planning, and we spent six months re-evaluating our vision, mission, and strategic goals. In November 2021, the Trustees formally approved a new long-term strategy alongside a three-year operational and organisational plan and budget for 2022 to 2024. This was mentioned in the “Our future plans section” of our annual report and accounts for 2021.

Long-Term Strategy

As the UK’s leading leukaemia charity, we exist to improve the lives of people affected by leukaemia and related blood cancer types – myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

Our long-term strategy aims to set out afresh Leukaemia Care’s vision, mission, values and five clear goals to guide us forward. It is a statement of intent. For the first time ever, we have made this a public document that can be accessed in the “About us” section of our website, allowing us to clearly and publicly state who we are and what we stand for, encouraging people to join us in our mission to create a future where everyone gets the best possible diagnosis, information, advice, treatment and support.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

This public statement helps clarify our positioning as the UK’s leading leukaemia charity, covering everything related to leukaemia and related blood cancers (e.g. support, information, campaigning, researching patient experience, being a strong voice for the leukaemia community), except funding clinical research.

We will continue to develop collaborations with other charities depending upon their focus, organisational similarities or topic specific expertise. We recognise that other organisations are better placed to provide this support for other forms of blood cancer - such as lymphoma or myeloma, and we continue to signpost people to the best possible information, advice and support for their particular circumstances (e.g. Lymphoma Action, Myeloma UK).

Operational Plan

The new operational plan has been reorganised to align with our long-term strategy, as the first steps towards achieving our long-term goals. Whilst it contains many activities from previous years (as well as some new ones), it is now organised by our strategic goal (why we are doing it) rather than a delivery plan (who or how we will deliver it).

This recognises our need to work as a whole organisation, rather than individual teams, to achieve our collective goals. Whilst an individual or a department may lead on an activity, we work as one team and seek input and feedback from colleagues across the whole charity where appropriate.

Performance Measures

Our performance measures help us measure our progress towards our goals. For each activity at Leukaemia Care, we have set both targets (effective) and stretch targets (highly successful) for 2022. All targets are based on historical outcomes and expected outcomes in 2021 where a service is already in place, and for new services we have used informed assumptions. These will be used for reporting, with all targets for future years reviewed considering the performance and outcomes from the current financial year.

Organisational Plan

The organisational plan outlines our commitment to developing the charity through supporting employee wellbeing, effective recruitment and induction, targeted staff development and training, a performance management process that aligns with behaviours and our organisational values, and effective recruitment and management of volunteers towards delivering on our long-term strategy. It recognises that internal communication is vital, contributing to employee wellbeing as well as improving the delivery of our key objectives. We are committed to consulting with employees on key initiatives such as flexible working, wellbeing and internal communications, as well as other key topics that arise.

Development Process

The proposals within the operational plan are fully costed and seek to build upon measured outcomes from previous years and evidenced proposals from across Leukaemia Care with new opportunities and ideas.

At the centre of this plan is listening to and understanding the experience of people affected by leukaemia, MDS and MPN. This tells us why we do things. It starts with obtaining evidence through patient surveys (such as the Living with Leukaemia project and annual feedback survey) and external projects (such as Blood Cancer Alliance’s work on unmet needs). But it also comes through seeking individual inputs more directly through our patient and medical advisory panels.

In 2021, we incorporated a much wider range of internal perspectives as part of the planning process. At the outset of the process, Trustees were invited to take part in a facilitated discussion with the CEO to seek their views, suggestions and long-term ambitions for the charity. There was a high level of alignment across the board. Feedback focused around perceptions of the charity, unmet needs for patients and healthcare professionals, organisational strengths and weaknesses, prioritisation of activities, external opportunities and challenges, differentiating Leukaemia Care from other blood cancer charities and investment of reserves into developing the organisation and it’s activities. Insights from these discussions have primarily informed the development of the longterm strategy and operational plan.

Employee input was sought through an anonymous survey, with responses analysed to consider both overall aligned perspectives and areas of differing views. Key themes that emerged from this exercise included inspiring people to support us by better demonstrating our impact, improving the way we do things internally to improve outcomes for patients and understanding what has the greatest impact on the wellbeing of employees. Following

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

the survey, employee focus groups were used to further explore or clarify these topics. These insights are at the core of developing the organisational plan, as well as providing a more nuanced view and insights as part of the operational plan.

Conclusion

As a result of this process, our new plan for 2022 to 2030 represents our best current thinking on the way to make our vision a reality, as soon as possible. But it is open to challenge, new ideas and change as things develop. We are more committed to achieving our vision than to any particular plan we happen to be following right now. We recognise this plan is ambitious and will be challenging to implement in its entirety. It is at the core of our values as an organisation to have ambitious goals and to set ourselves high standards to achieve them. We owe it to people affected by leukaemia, MDS and MPN to do our utmost to advance our vision, as quickly as possible. We owe it to people who donate their money to spend it in a way that makes this vision come true.

Our achievements

Improving diagnosis – through awareness and early detection

We achieve this through our annual Spot Leukaemia campaign, targeting awareness days like World Leukemia Day and through our education work with GPs and other healthcare professionals.

In 2022 we continued our collaboration with Leukaemia UK for our Spot Leukaemia campaign, focusing on raising awareness of the symptoms of leukaemia in the over 65’s. We soft-launched at the end of August with our new creative video (featuring Henry the Parrot) and 36 patient stories along with national and regional PR. Within the first week we received 509 pieces of press both nationally and regionally as well as TV.

Overall the campaign reached over 15 million people on social media, with 161,285 views of our campaign video (Henry the Parrot) which raised awareness of the main symptoms of leukaemia; fatigue, bruising, bleeding and infection, urging people to go to their GP and ask for a blood test if they experienced these symptoms.

Throughout the year, we ran mini campaigns on awareness days such as World Leukemia Day, MDS Day, Know AML Day and World Cancer Day. World Leukemia Day (4 September) which was launched by Leukaemia Care in partnership with worldwide patient advocacy groups reached 30,185,694 people on social media exceeding the 8 million reached in 2021.

We continue to provide education for general practitioners (GPs) through our GP online learning modules via the Royal College of General Practitioners (RCGP) and Gateway C, including two new webinars for GPs. In person events with GPs prior to COVID had good uptake and feedback, but the RCGP has no plans yet to return to local in person training events. However, we continue to attend and staff information stands at conferences aimed at GPs such as the Best Practice conference. In 2023, we will review our approach and investigate ways of promoting our online learning modules.

Ensuring everyone receives high quality information, advice and support

Leukaemia and blood cancer is highly complex. We know that at diagnosis people are significantly less likely to understand what is wrong with them than for other forms of cancer. Many are left worried and confused.

We know that high quality information, advice and support is key. Whilst most people receive information about their blood cancer, few receive information about emotional, practical and financial support. Information is also more likely to be provided at diagnosis, with a drop off after treatment finishes. We are working to stop this.

This area of work covers our core frontline services for patients and their families. Our written information (hard copy and online), videos, podcasts, webinars and conferences. Our advice service incorporating the helpline, WhatsApp, email, advocacy casework and welfare advice, and hospital hubs. Our support services; support groups, online forums, one to one buddy support, financial grants, counselling and free wills.

In 2022, we adopted a new format for information suites of leukaemia information, with all the information tailored by leukaemia type and creating a pathway of different points where people can access information (e.g. diagnosis, starting treatment). This is a significant project and in 2022, we completed the new format for acute lymphoblastic leukaemia (ALL) resulting in 10 new booklets.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

We continue to offer our existing booklets alongside the new formats and in 2022, distributed 13,862 hard copies and 15,118 digital copies were downloaded from our shop. We also gained accreditation with the Patient Information Forum “PIF Tick” scheme for patient information ensuring our information continues to be produced and reviewed in a robust way.

“I am a recently diagnosed Chronic Myeloid Leukaemia person and have felt quite scared by my recent diagnosis. However, having read this booklet, I felt much more positive. The practical advice and living beyond the diagnosis has made me feel less scared about the future.” Feedback from patient on our Living with Chronic Myeloid Leukaemia (CML) booklet

We also provide information on the rarer leukaemias recognizing that these patients face additional challenges in both getting up to date accessible information on their cancer and meeting fellow patients who share their condition.

“It is very hard to find information about this rather rare condition but this leaflet is without doubt the best and most comprehensive summary I have found. A must for any recently diagnosed people.”

Feedback from a patient on our Large Granular Lymphocytic Leukaemia (LGLL) booklet

We recognize that people like to access information in different formats not just booklets and that many would like an introduction to our services. We sent out 1,005 Welcome Packs introducing people to our services and signposting them to our booklets, blogs, monthly podcast, videos and webinars.

We ran 20 webinars on a variety of topics which were all recorded so they can be accessed time and time again for people looking for information and debate on key topics. Our webinars were viewed 16,352 times on social media.

“I have been watching Leukaemia Care webinars since the start of lockdown and they have always been really interesting, informative and very supportive. I found this last one particularly pertinent, as I have been told by my consultant that I will need treatment soon. Thank you so much, I feel less scared now. I feel well informed and confident in the treatment I have been offered.”

Patient feedback on CLL webinar

Alongside our information, we offer the opportunity to seek advice and support from our clinical nurse specialists, trained advocates and welfare advisors. We provided 906 people with timely advice and support via our helpline, WhatsApp and email with an average feedback score of 4.75 out of 5.

“This is the only place I can come to speak about my leukaemia, having a nurse who understands my condition available at the end of the phone is invaluable.”

“It is amazing to have such a specialist service available for free.”

Feedback from leukaemia patients

Our Advocacy caseworker supported 266 people with issues such as obtaining travel insurance and COVID booster vaccinations, making complaints about hospital care and getting support with additional needs such as enduring mental health problems alongside a blood cancer diagnosis. They work closely with our Welfare Officer as many people have varied and complex needs that also touch on finances.

"Your organization throughout me having to shield has been so helpful to me, supporting me with issues at work but also keeping blood cancer patients updated as to the latest regarding Covid. A big thank you,"

Our Welfare Officer supported 217 people with the majority of queries being classed as major i.e. complex, helping people to apply for benefits, challenge benefits decisions, apply for grants of money and goods and processing applicants for our Financial Hardship Fund, Exceptional Hardship Fund and CAR-T Away from Home Fund. The cost of living crisis has had a severe impact on people’s finances already impacted by a leukaemia diagnosis.

“Dad had his letter today to say he is entitled to the lower rate of attendance allowance. Thank you so much for your help as he wouldn’t have applied and he would have been missing out.”

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

“I just wanted to let you know that my PIP application has been processed and I have been awarded the enhanced rate for both daily living and mobility! I am delighted as this now means I can apply for a blue badge! Thank you so much for all your support which without, I am sure, I would not have been able to get the enhanced rate. Thank you so much”

“…being able to plan some great summer holiday childcare while I’m in hospital having my stem cell transplant without worrying about how we were going to pay for it is such a blessing and a massive relief. It will give them something to look forward to and enjoy during such a difficult time. Your support has enabled my young children to be children. Thank you so much for all the hard work and support you have given to me.”

We have ten hospital hubs based in Good Hope (Sutton Coldfield), Solihull Hospital, Heartlands Hospital, the Worcestershire Royal, St James Hospital in Leeds, Southampton General, University of Bristol Hospital, The Christie in Manchester, University College London Hospital and Freeman Hospital, Newcastle. Our hospital support workers provide emotional support, information and advice to patients and their families within haematology departments and on hospital wards, at diagnosis and throughout their treatment. In 2022, we supported 199 people, in person and by phone as needed by the hospitals.

“[HSW] is an asset to our team, supporting patients and us with information, a listening ear, and her time. So many of our patients have been lucky enough to have access to her in her role as Hospital Support Worker, and her support has been invaluable, helping them through very challenging and difficult times. Any questions we as Clinical Nurse Specialists have about the services and support available from Leukaemia Care have been answered quickly by the [HSW], which our team have found very beneficial and has improved our ability to provide the best support to our patients”.

Feedback from Clinical Nurse Specialist at St James Hospital, Leeds

We run 38 support groups (in person, hybrid and online only) supporting 1,911 people in 2022 (1,600 in 2021). Many of our members are still uncomfortable about meeting in person due to COVID and clinical vulnerability, especially in Q2 of 2022 when patients were finding it difficult to access spring COVID boosters. Our specialist national support groups are well received especially by those with rarer leukaemias. New groups launched in 2022 include LGLL National, Northern Ireland National, Scotland National and Parents & Families of Children with Leukaemia National Support Group.

We also run an online forum via HealthUnlocked and closed Facebook groups that collectively supported 4,333 people.

“The support and solidarity of the groups and my telephone buddy helps me to remember that I’m not alone and encourages me as I navigate life after cancer. Thank you. Leukaemia Care!”

Feedback from Teesside support group member

"Thank you for the meeting, it was useful and good to speak to others in the same situation as myself. I hadn't thought of myself as a carer but my husband encouraged me to join the meeting! Your email is full of useful information, thank you. Everything still seems a little overwhelming at times but the support from yourselves has really helped us both. Thank you again”

Feedback from wife of ET patient

Our buddy services matches patients and families with people who have a similar diagnosis for emotional support. In 2022, we matched 131 patients for long-term or short-term buddying with some volunteer buddies supporting multiple patients.

“I just wanted to let you know that my buddy is a huge support, and she rings me fortnightly. [Buddy] as I am sure you know, has been through the same CLL treatment as I have had and helps me in so many ways. I was surprised when my telephone consultation re Venetoclax etc was reduced from four weekly to every 8 weeks, but [Buddy] reassured me this was completely normal. She is a very good listener, and such a help. My husband has been, still is very ill with lung & other problems, and [Buddy] always asks me how he is. We talk about all sorts of other things, like gardening which we both enjoy. Thank you so much for partnering the two of us.” Feedback from CLL patient

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

We also started a pilot CAR-T buddy scheme with Great Ormond Street Hospital with one parent ready to start supporting another family. In 2023, we will focus on growing this service which is still in its early stages.

We recognize that a leukaemia diagnosis can have a negative impact on people’s finances especially during a cost of living crisis. In 2022, we awarded 465 hardship grants of £100 or £200 and 11 exceptional hardship grants of up to £1,000. Due to unprecedented demand, our Hardship grants ran out in September however, in partnership with Leukaemia UK, we launched a Cost of Living with Leukaemia Fund in December 2022 awarding £100 hardship grants.

We also launched our CAR-T Away from Home service providing patients undergoing CAR-T treatment and their families access to paid hotel rooms and a £500 grant towards increased costs. This is a partnership with our new corporate partner, the Dalata Hotels Group. Launched in September, we awarded three grants in the final three months of the year, helping these families with the financial costs of travelling to access this innovative form of treatment. In 2023, we will work on building relationships with hospitals to ensure they are aware of the service and know they can make an easy referral.

Our counselling fund provides much needed access to specialist support during a time when NHS counselling resources are stretched or non-existent. In 2022, we supported 56 people (35 in 2021) seeking counselling support with issues such as coming to terms with relapse or terminal illness, living with a chronic leukaemia and parents coping with a child’s diagnosis.

“I can’t express how grateful I am to Leukaemia Care for providing this fund – not just for the financial side of it (which is very generous), but also for how easy it was to get everything set up. I don’t think I’d have been able to afford private therapy or had the patience to wait for an NHS appointment, so having such quick and simple access to free counselling made such a huge difference.”

We believe everyone diagnosed with a potentially life limiting illness such as leukaemia should have the chance to make a will. In 2022, 53 (41 in 2021) people made a will using our free wills service with many choosing to leave a gift in their will to Leukaemia Care although there is no obligation to do so.

Tackling issues that impact people’s lives

This area of our work covers our advisory panels (medical and patient), our patient experience research, our policy and public affairs, campaigns and external advocacy projects.

Our medical and patient advisory panels provide feedback on not only our strategic plans but also our day to day work, to ensure it meets the needs of people affected by leukaemia and other forms of blood cancer. We have 96 healthcare professionals including specialists in the four main leukaemias as well as MDS, MPN and rare leukaemias. These include consultant haematologists, clinical nurse specialists, GPs, psychologists and district general hospital doctors. Our patient advisory panel of 52 includes acute and chronic leukaemia patients, those with rare leukaemias, MDS and MPN.

We are always looking for new members to join our panels especially the patient panels both to ensure they reflect the diverse blood cancer community but also in acknowledgement that people’s circumstances change. For instance, some people have been in remission for a while and choose to leave that part of their experience behind them - this is completely understandable.

With regards to our policy and public affairs work, generally, political changes continued to make it hard for us to keep stakeholder engagement up. We welcomed the new ministers with various responsibilities for Cancer, Primary Care and the Secretary of State for Health and Social Care but received no response. This is consistent with the experience of other charities when reaching out to the main stakeholders.

We collaborated with the Department of Health and NHS England on their winter vaccination campaign by creating co-branded assets to share on social media featuring two leukaemia patients. The aim was to encourage more people to come forward and get their booster vaccines, and the graphics were retweeted by the DHSC channel, increasing our reach online.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

The latest draft of the 10-year Scottish Cancer Strategy was released, and following calls from charities including Leukaemia Care the draft included specific consideration of blood cancers for the first time, as far as we are aware, in the Earlier and Faster Diagnosis section: “It is recognised that not all cancers can be conventionally staged so additional measurements, such as emergency presentations, will be required to track progress and improvements in other cancer types, including blood and brain”. Although we want to see more emphasis on blood cancers in the final strategy, this is significant because previous strategies have failed to include blood cancers in early diagnosis. Later drafts have also acknowledged the need to frequently publish and share data. We will continue to respond to future drafts on behalf of people affected by leukaemia.

Each of the two campaigns we ran was different in what was most effective; Watch, Wait Worry showed the importance of patients telling their MPs about an issue too, whereas the Spot Leukaemia campaign showed the importance of a good external environment.

Watch, Wait, Worry campaign launched in April

Our ‘Left to WatchWaitWorry’ campaign aims to improve the lives of people with chronic lymphocytic leukaemia (CLL) on Watch and Wait, by calling for additional support and information. It is estimated that there are currently around 13,300 chronic lymphocytic leukaemia (CLL) patients living on Watch and Wait as their current treatment option. A time which patients often call ‘Watch and Worry’.

As part of the campaign, we secured nine written parliamentary questions asked by MPs in Westminster and two parliamentary questions in Scotland on the WatchWaitWorry media campaign. This includes a response from the Cabinet Secretary for Health in Scotland. This gave us insights that we could use to inform our next steps on the campaign, such as including it in our response to the upcoming 10 year cancer plan and Scottish Cancer strategy. This included information about whether data is collected on CLL patients using mental health services and whether or not governments intend to include those on active monitoring in the upcoming plans.

On social media the WatchWaitWorry campaign saw some good engagement from parliamentarians, including tweets from Jeffery Donaldson MP, Robert Buckland MP, Emma Lewell Buck MP, Martyn Day MP, Alex Rowley MSP, Naomi Long MLA, among others.

We had a meeting with Sir George Howarth MP on this campaign and as a result, he posted about the campaign on his website, submitted written parliamentary questions and wrote a letter to the Secretary of State for Health and Social Care. In devolved nations, we met six politicians virtually. We targeted those politicians who had engaged with the emails from the constituents for meetings.

We presented the WatchWaitWorry media campaign report to the RM partners cancer alliance Haem-oncology pathway group meeting. There were haematologists across the West London region in attendance and we discussed the issues patients face and how to work together to improve them. We informed them that we were planning to develop guidelines for secondary care professionals on Watch and Wait which they would welcome. They also suggested we should do similar guidelines for primary care.

Additionally, we hope to pick up the work on best practice guidelines for supporting patients and submit a proposal to the British Society of Haematology guidelines committee by the end of the year.

Malignant Diagnosis, Surely campaign

Can you imagine being diagnosed with a condition and your healthcare team omitting to mention it is a type of cancer? Yet this has been the case for some people diagnosed with myelodysplastic syndromes (MDS).

MDS is a type of cancer and it is important that everyone calls MDS a cancer. By not mentioning the term ‘cancer’ immediately at diagnosis, and not explaining low-risk vs high-risk, there is a risk that patients find out by chance that MDS is a type of cancer, as soon as they look up any information after their initial appointment, such as using the NHS website. The shock of that discovery, when alone, and the lack of medical staff to check with can be traumatic for many. As a result of misunderstanding their diagnosis, patients might not receive the support that they are entitled to, such as employment rights and access to psychological and financial support.

That’s why Leukaemia Care and MDS UK are working together as part of a Malignant Diagnosis, Surely? campaign. We launched a petition to insist that NHS England treat MDS as a cancer in everything they do.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

We continue to play an active part in a variety of coalitions and alliances both national and international such as Cancer 52, the Blood Cancer Alliance, the Acute Leukaemia Advocates Network, the CML Advocates Network and the Chronic Lymphocytic Leukaemia Advocates Network. This is by no means an exhaustive list, and is just one part of our commitment to collaborate with other charities.

Advancing treatment and care

This area covers our engagement with healthcare professionals – providing training and raising awareness of our services as well as our work on improving access to treatments.

Our Regional Coordinators raise awareness of our services within hospitals across the UK and in 2022, contacted 212 hospitals with both.in person visits and virtual meetings. They are also responsible for running our support groups and ensuring members receive the right information and support by signposting to our services.

“[RC] runs successful support groups for our group of patients and the feedback has been excellent, providing a safe and informative platform for people affected by leukaemia to meet and talk to others”. Feedback from a Clinical Nurse Specialist at St James’s Hospital, Leeds

“RC is a breath of fresh air. She organises all our support groups and makes patients feel at ease. It has been a pleasure to work with her over the last few years in facilitating a support group for the people of Barnsley.” Feedback from a Clinical Nurse Specialist at Barnsley District General Hospital

Leukaemia Care also offers an online newsletter to healthcare professionals and in 2022, this had 1,904 subscribers. This provides information about our services as well as free training for nurses.

We offer 12 free online courses for nurses ranging from 1 to 4 hours on topics such as CAR-T, emergencies in leukaemia, end of life and acute leukaemia, extravasions, GVHD, supportive care, MPNs, understanding blood and its components, diagnosis of leukaemia, and epidemiology, aetiology and risk factors. The average feedback score from users was 4.25/5 with 217 subscribers in 2022.

Our Acute and Chronic Leukaemia Nurse Forums bring together haematology specialist nurses and allied healthcare professionals with an interest in acute/chronic leukaemia patient care to build capacity and provide opportunities for best practice sharing and networking. In 2022, 52 nurses attended these forums with topics discussed including research projects, vaccinations and leaflets for GPs about CLL.

Leukaemia Care have committed to be actively involved in all relevant Heath Technology Appraisals for leukaemia, MDS and MPN to ensure that we work to obtain access for patients and represent their views when decisions that affect them are being made. In 2022, we were involved at every stage of the health technology appraisal process in 97% of appraisals and were involved at some stage of the process in 100% of appraisals. In 85% of appraisals, patients were directly involved sharing their experience to effect change (e.g. by attending a NICE committee meeting). Outcomes (when the embargo on a decision is lifted by the appraising agency) are reported online via our website and social media as well as in our newsletters and patient magazine, Leukaemia Matters.

Creating a narrative to better reflect the reality people face

Patient stories, press and social media all play a critical role in ensuring that patients and their families as well as the public understand the reality of living with leukaemia.

Sixty-three people shared their story with us to support others and raise awareness of the challenges they face with half of these having benefited from our services. We also updated 51 stories shared in previous years with people and their relatives talking about returns to work and study after treatment, early retirement, ongoing challenges with late effects, and also facing bereavement and loss. Fifty people keen to give back and raise awareness of the support available from Leukaemia Care provided testimonies to be used to encourage people to reach out for help.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

In 2022, we received 56 pieces of national and 651 pieces of regional press coverage with an estimated reach of 1.4 billion. Our social media reach continues to grow especially as part of our Blood Cancer Awareness Month campaign in September (2.5 million in 2022). We invest in social media advertising and paid Google advertising to reach as many patients and potential fundraisers as possible, raising awareness of our free services and the opportunity to volunteer and raise money to support leukaemia, MDS and MPN patients and their families.

Visitors to our website have increased with 1.9 million visits and 2.6 page views in 2022 (1.5 million and 2 million respectively in 2021). Our symptoms of leukaemia information and blogs continue to be our most visited pages. The importance on thinking mobile first is even more prominent in 2022 as we saw a 29% increase in web traffic coming from a mobile device. We expect this to increase year on year and therefore we will have to make sure that any content and website integrations are fit for a mobile first platform.

The bounce rate for the LC website continues to remain high, however, plans to restructure one of the larger areas of the website are in progress and we would hope this changes once complete. It would help our high bounce rate as the user journey will become more streamlined to deliver relevant content to the user. Going forward in 2023, Google Analytics will be putting less emphasis on bounce rate as it will collectively rate web pages through ‘engagement rate’ which will take into consideration the bounce rate and time spent on a landing page.

Funding from legacies

Legacies enable the charity to plan for the future, pilot new services and expand existing ones. Without the generosity of people who chose to remember Leukaemia Care in their will, this would not be possible. In 2022, we benefited from £411,669 from gifts in wills from the estates of William Davidson, Edward Manning, Violet Whitehead, Beatrice Youngman, Charles French, Jonathan Lovick, Judith Crompton, Lilian Taylor, Alexander McCubbin and Vera Philips. We wish to honour their memory for their support for leukaemia patients and their families.

We promoted our free wills scheme during Free Wills months in March and October. Under this scheme, people can make a simple will (online or by phone) and can leave a gift to the charity if they wish. We encourage anyone diagnosed with a life changing illness such as leukaemia to ensure they have an up to date will regardless of whether they choose to leave a gift to Leukaemia Care. In 2022, 53 people took up the offer of a free will from the charity with legacy pledges of approximately £348,729.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Our plan to fund our activities – now and in the future

Our ambitious fundraising plan seeks to secure sustainable growth for the future, raising more money to ensure we can achieve our strategic goals. The charity’s ability to deliver much needed activities (information, support, advice, campaigns) is reliant on our fundraising. We cannot improve the way we help people affected by leukaemia, MDS and MPN without expansion in this area.

As explained earlier, 2022 will go down on record as the year we raised over £2 million for the first time representing our best year ever and a 59% growth on income from 2021. This includes a strong legacy year but also better than expected performance from pharmaceuticals, Unicornfest, Ride London and In-Memory giving.

However, there were areas that did not perform as well as expected and some new initiatives that did not work first time round and need refining. Running events including the London Marathon suffered from poor sign-ups, dropouts and deferrals of running places to following years which impacted 2022 income. Community fundraising also took a hit with our new community challenges failing to sign up enough participants.

Our fundraising team grew from six to sixteen members to allow the charity to develop new income streams and grow existing ones. We recruited expertise and resource in grants and trusts, digital, corporate, events and community fundraising.

New initiatives and partnerships in fundraising

Unicornfest

This is Leukaemia Care’s first art trail and will be held in Bristol during summer 2023, raising both awareness and funds for the charity. The unicorns, painted by local artists will be placed throughout Bristol allowing locals and visitors to explore the city via a colourful and uplifting trail that ends with a ticketed farewell event and separate auction in autumn 2023. We ended 2022, with £227,000 raised in sponsorships from almost 40 sponsors. We do not expect further income until 2023 when the unicorns are auctioned. The art trail has been a huge undertaking for the charity with a steep learning curve but we are confident it will not only raise significant income but open the door to longer term corporate partnerships.

Dalata Hotels Group corporate partnership

We are delighted to be working with Dalata Hotel Group PLC from 2022 until 2025. They are the largest hotel operator in Ireland, with a growing presence in the United Kingdom and continental Europe and they will be supporting Leukaemia Care through its Maldron and Clayton hotel chains in England, Scotland and Wales.

The Dalata partnership will support leukaemia patients by providing long stay accommodation close to the hospital that can administer a new treatment called CAR-T. A limited number of specialist hospitals in Great Britain offer this treatment and the locations match conveniently with Dalata hotels, with this project ensuring it is possible for patients to get the treatment they need. Individual hotels will also be fundraising in aid of the charity.

World Gaming Day

Leukaemia Care launched World Gaming Day on the 22 October 2022. This is an opportunity to meet up with friends, play games and raise money for charity. Leukaemia Care sold World Gaming day packages to other charities making it easy for them to run their own World Gaming day fundraising event. Charity partners included Action for Children, Stroke Association, Epilepsy Society and more.

Unfortunately, uptake was limited for this new form of fundraising. We will not dismiss the concept as we believe it has merit, but we think this may take longer to develop and refine as an income stream.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Funding from legacies

Legacies enable the charity to plan for the future, pilot new services and expand existing ones. Without the generosity of people who chose to remember Leukaemia Care in their will, this would not be possible. In 2022, we benefited from £411,669 from gifts in wills from the estates of William Davidson, Edward Manning, Violet Whitehead, Beatrice Youngman, Charles French, Jonathan Lovick, Judith Crompton, Lilian Taylor, Alexander McCubbin and Vera Philips. We wish to honour their memory for their support for leukaemia patients and their families.

We promoted our free wills scheme during Free Wills months in March and October. Under this scheme, people can make a simple will (online or by phone) and can leave a gift to the charity if they wish. We encourage anyone diagnosed with a life changing illness such as leukaemia to ensure they have an up to date will regardless of whether they choose to leave a gift to Leukaemia Care. In 2022, 53 people took up the offer of a free will from the charity with legacy pledges of approximately £348,729.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Funding from grants and trusts

Leukaemia Care receives no statutory funding, but it does receive grants from independent trusts and other funders. These grants are an increasingly important part of our income and significantly improve our ability to deliver services to leukaemia patients and their families across the UK. We would like to thank the following funders for their kind support in 2022:

The 29th May 1961 Charity

The Blakemore Foundation

The Boots Charitable Trust

The Burford Trust

The Donibee Charitable Trust

The Edward and Dorothy Cadbury Trust

The Hospital Saturday Fund

The Hugh Fraser Foundation

The Joseph Strong Frazer Trust

Leukaemia UK The Liz and Terry Bramall Foundation

Medicash

The National Lottery

The Patrick Trust

The Roger and Douglas Turner Charitable Trust

The Santa Barbara Heights Charitable Trust

The Templeton Goodwill Trust Tyne and Wear Community Foundation The Yardley Great Trust

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Funding from the pharmaceutical industry

The charity works with the pharmaceutical industry to ensure that the interests of patients are considered when developing new drugs and treatments for patients.

In addition to our patient advisory work, Leukaemia Care receives funding from a range of pharmaceutical companies. Any funds received from the pharmaceutical industry are received and dispersed strictly within the guidelines laid down by the Association of the British Pharmaceutical Industry (ABPI) and Leukaemia Care’s own Code of Practice (see website).

To ensure that we remain financially independent, limits are placed on all types of funding. We do not allow the total level of funding received from the pharmaceutical industry to exceed 25% of our total annual income. Nor do we allow the funding received from an individual company to exceed 10% of our total annual income.

In 2022, Leukaemia Care had our most successful year ever with £402,576 secured in donations from the following pharmaceutical companies.

Abbvie £15,000 for our AML Support Project
Amgen £10,000 for core funding
Astellas £25,000 for our Emotional Support Project
AstraZeneca £25,000 for our Advice, Information and Support Project
Autolus £5,000 for core funding
BeiGene £20,000 for core funding
Bristol Myers Squibb £15,000 for core funding and £15,000 on behalf of the Blood Cancer Alliance
Gilead £40,000 core funding
Incyte £30,000 for our Advice, Information and Support Project
Janssen £5,000 for core funding
Jazz £40,000 for our Advice, Information and Support project
Kura Oncology £12,204 for core funding
Kyowa Kirin £5,000 for core funding
Lilly £5,000 for core funding
Mallinckrodt £22,417 for our Advice, Information and Support Project
Otsuka £10,000 for our Advice, Information and Support Project
Pfizer £20,000 for core funding and £23,135 for the AML Testing Project
Pleco Therapeutics £5,000 for core funding
Servier Labs £5,000 for our Advice, Information and Support Project
Takeda £30,000 for core funding and £20,000 for the CAR-T Project

We also received a grant of £15,000 from Gilead towards our Unicornfest art trail, not included in the figures above, with all other pharmaceutical work on this project to take place in 2023.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Financial review

The results for the year are set out in the financial statements commencing on page 32. The financial statements show incoming resources for the year of activities of £2,139,494 compared to incoming resources in 2021 of £1,346,169. Trustees would like to thank all staff and volunteers for the continuing hard work and commitment that have made this possible.

Total reserves stand at £3,127,406 (2021: £3,032,035) of which £155,918 (2021: £71,581) was restricted in application and £1,347,823 (2021: £1,087,127) were designated by the trustees to match the tangible fixed assets of the charity and fund certain projects identified as being required in the immediate future. Those designated funds connected to tangible fixed assets relate predominantly to the freehold property and are likely, given current market conditions, to remain whilst the relevant charitable entity continues to own title to the same. Funds remaining for general use were £1,623,665 (2021: £1,873,327).

The Trustees consider the results for the year to be satisfactory.

Risk assessment and management

We carry out an annual detailed review of the charity's activities and produce a comprehensive three-year strategic plan which sets out the major opportunities for the delivery of patient support. The Trustees monitor progress against the strategic objectives set out in the plan quarterly, in addition to the annual review. As part of this process the Trustees have implemented a risk management strategy, which comprises:

The strategic plan referred to above focuses on the delivery of care and support to anyone affected by blood cancer. Successful implementation of the plan is dependent upon the charity having the necessary resources available (financial and otherwise) and for the prudent and effective management of such resources.

Our plans for 2023 and beyond

As we seek to grow our impact, we are currently limited by our income levels. Whilst we have high levels of reserves which would enable us to initiate most activities, our current income levels would not enable us to sustain those activities long-term. As such, our plan involves ‘investing for growth’ by focusing on investing from reserves into new fundraising activities to grow our income, before committing additional expenditure to service delivery from this new income.

Leukaemia Care remains in strong financial health, with total assets of c. £3.1m (including the office) and funds available for use of c. £1.6m.

Leukaemia Care’s reserves policy is to hold sufficient funds to cover between six to nine months of budgeted ongoing expenditure (2022: 7.1 months). We recognise that money is donated to advance our charitable purposes. As such, our policy is to only hold reserves for a particular objective or to mitigate a particular risk, to avoid tying up money unnecessarily. As such, it is important we continue to invest our reserves to enhance the impact we can have.

We propose to undertake a significant investment from reserves in 2023. To facilitate better understanding of our expected financial position throughout the year, we have set the 2023 budget and targets in January using year-end figures for 2022 and forecasted quarterly for 2023 (income and expenditure). We intend to report against this at Trustee meetings. To accompany the 2023 - 2024 plan, we have produced a 5-year forecast to 2027, to show the longer-term impact of investing into new income streams, some of which (e.g. legacies) take time to bear fruit.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Mitigating Risks

At its centre, the plan includes a strong focus on managing risk, to control our approach to generating and spending new income. Whilst we expect to raise some new forms of income within our baseline plans, given the uncertainty quantifying new income streams this income is not already committed to new expenditure. Additional expenditure is subject to increasing our income or securing restricted funding for the activity, which is only triggered when we are comfortable that it is affordable.

But we have also put in place several other protections beyond this, including:

Performance Measures

Our performance measures help us measure our progress towards our goals. For each activity at Leukaemia Care, we have set both targets (effective) and stretch targets (highly successful).

All targets are based on historical outcomes from 2022 where a service is already in place, and for new dynamic activities we have used informed assumptions. For new dynamic activities, we have set targets per month or quarter, in recognition that these activities may be started at any point through the year.

These performance measures will be used for reporting, with all targets for future years reviewed considering the performance and outcomes from the current financial year.

Our Reserves Policy

Leukaemia Care’s reserves policy has been developed in line with best practice guidance to maintain resilience within the finances of the Charity. By developing an intelligent reserves policy with a clear understanding of income and expenditure, we aim to consider and mitigate against financial risk more effectively.

We recognise that money is donated to advance our charitable purposes. As such, our policy is to only hold reserves for a particular objective or to mitigate a particular risk, to avoid tying up money unnecessarily.

Leukaemia Care has a separate Investment Policy which considers the best use of reserves for generating financial return, preserving capital value, and meeting unanticipated cash flow requirements. For the purposes of investment, Leukaemia Care has divided its reserves into two those expected to be held for a long-term time horizon and those that may be needed in the short term.

It is Leukaemia Care’s policy to express reserves in terms of ‘months of expenditure’ for the purposes of external

communications.

Our policy identifies three factors requiring the charity to hold reserves. These are considered in the context of both individual risks and by summation (the addition of multiple risks happening at once):

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

ii. Provision to absorb setback - i.e. predominantly related to income-based risk.

iii. Funds designated for specific commitments – i.e. operational plan commitments, including forecast deficits or existing committed projects and activities.

In line with the considerations above, Leukaemia Care’s policy is to hold sufficient funds to cover between six to nine months of budgeted ongoing expenditure (£1,623,665 – 7.1 months as of 31/12/2022). Ongoing expenditure excludes one-off projects and depreciation, which are met through designation.

Our policy is subject to annual review by the board of Trustees, with the reserves reviewed in line with the policy at budget setting time and in time for the new financial year. Notwithstanding this, the reserves amount is calculable at any point of the year if required, as the financial position of the charity changes or plans alter.

Our Investment Policy

The Trustee Board regularly monitors cash and investments against objectives and risk profile. The investment policy is reviewed annually, and recommendations made to Trustees. Day to day investment management is delegated to an authorized, professional investment advisor, regulated by the FCA.

Our investment policy aims to produce the best financial return within an acceptable level of risk. The investment objective for the long-term reserves is to generate a return in excess of inflation over the long term but also to be ‐ available at short notice to support the on going activities of the Leukaemia Care.

The investment objective for the short-term reserves is to preserve the capital value with a minimum level of risk. Assets should be readily available to meet unanticipated cash flow requirements.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Structure, governance and management Constitution

This is the third annual report of Leukaemia Care. Leukaemia Care was registered as a private company limited by guarantee on 28 March 2019 (Registered No: 11911752). It was then registered with the Charity Commission on 13 June 2019 (Registered No: 1183890) and with the Scottish Charity Regulator on 9[th] December 2019 (Registered No: SCO49802).

Trustees and their role

The trustees are responsible for the governance and strategy of the charity. A minimum of five and a maximum of 12 trustees in office at any one time are required by the constitution. At each AGM one-third of the trustees, must retire from office but may stand for re-election. A Trustee’s term of office is not restricted, and they receive no remuneration for their duties. They may claim reasonable expenses incurred such as travel to trustee meetings. The trustees meet six times a year (currently online or hybrid meetings) and delegate day-to-day running of the charity to the senior management team.

The Trustees who served during the year and up to the date of signature of the financial statements were: Mr Christopher R G Matthews-Maxwell (Chair)

Mrs W J Davies (Treasurer) Dr Emmanouil Nikolousis Ms E Wilson (Vice Chair) Ms Kate Stallard Mr Robert Heppell Mr Dharmesh Mehta Professor Mhairi Copland (Appointed 2 February 2022) Ms Carina Patterson Helen Knight (Appointed 4 May 2022) Dr Sarah Smith (Appointed 2 February 2022)

Recruitment, induction and training of Trustees

The Chair with support from their fellow Trustees and the CEO, identify the skills and insight required on the board to deliver the charity’s strategy. A volunteer role specification is drafted and approved before being advertised as widely as possible. This includes Leukaemia Care’s social media outlets, online recruitment sites, specialist publications targeting for example healthcare professionals as well as a direct approach to individuals identified as having the appropriate skill sets. Potential applicants are invited to submit a CV and if shortlisted for interview, will be interviewed by the Chair and another trustee. Successful applicants will be co-opted as trustees until their formal election at the next annual general meeting.

On appointment, the new Trustees attend an induction at our offices in Worcester (Government restrictions permitting during the pandemic) with the executive team and identify areas in which they may wish to take a special interest. They are provided with an induction pack including a copy of the constitution, recent trustee board minutes, accounts, financial reports, the charity’s strategy as well as helpful publications such as the Charity Commissions “The essential trustee”.

All Trustees are encouraged to attend Leukaemia Care’s webinars for further insight into the challenges facing patients, their loved ones and the healthcare professionals that look after them, and how Leukaemia Care is addressing them.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Our trading subsidiary

Ahead of the launch of our art trail Unicornfest, the Trustees of Leukaemia Care Limited decided to register a trading subsidiary – Leukaemia Care Trading Limited which was registered at Companies House on 21 April 2022 (Registered No: 14059389). Its Directors are Chris Matthews-Maxwell, Elizabeth Wilson and Wendy Davies who are also the Chair, Vice Chair and Treasurer of the parent charity, Leukaemia Care Limited. All trading activities relating to Unicornfest will go through the subsidiary company.

Our approach to fundraising

Leukaemia Care is registered with the Fundraising Regulator and as such agrees that when fundraising will do so in accordance with the Fundraising Promise and such of the Code of Fundraising Practice as applies to our fundraising methods. We agree to promote the Fundraising Promise (www.fundraisingregulator.org.uk/) and to include the Registration Badge on our fundraising materials where practical.

We are committed to protecting vulnerable people and others from unreasonable intrusion on a person’s privacy, unreasonably persistent approaches or undue pressure to give in the course of or in connection with fundraising for Leukaemia Care. As a result, the charity is signed up to receive suppressions under the Fundraising Preference Service and will actively promote this service to anyone enquiring directly to the charity about concerns with our fundraising ask.

In 2022, the charity received no suppression requests through the Fundraising Preference Service and one fundraising complaint as detailed below.

Leukaemia Care received one fundraising complaint relating to the discontinued charity bags regarding fly-tipping of bags. This was reported to East London Textiles Limited who until September 2019 were contracted to deliver and collect charity textile recycling bags on our behalf. An apology was also made to the person making the complaint along with thanks for bringing the matter to our attention.

Our complaints procedure can be found on our website https://www.leukaemiacare.org.uk/about-us/

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Senior management team

The Trustees delegate day-to-day operations of the charity to the executive team

Chief Executive Officer Zack Pemberton-Whiteley Chief Operating Officer and Deputy CEO Monica Izmajlowicz Communications and Fundraising Director Nicole Scully Our Patrons

We are very grateful for the warm support of our patrons, Lady Penny Mountbatten and Beverley Worboys.

Our President and Vice-Presidents

Our Vice Presidents ably led by Dr Taylor represent our history as well as taking part in activities such as chairing our conferences, contributing via our medical advisory panels, raising awareness of leukaemia and fundraising. we wish to honour the memory and service of Dr Noel Harker who sadly died 17 February 2022 after many years of steadfast support to the charity and blood cancer patients and their families.

President Dr Richard Taylor

Vice Presidents Ms. Sue Merchant Professor Claire Harrison Dr Robert Marcus Professor Andrew Pettitt Professor Antonio Pagliuca Ms Sheila Hegarty Mr Jason Eliadis Mr Roland Maturi Mr Christopher MAtthews-Maxwell Mr Peter Mondon Mr Anthony Gavin Mr Albert Podesta

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Medical advisory panels

Our medical advisory panel together with our patient panel provide insight into our strategy development, as well as assisting the charity with identifying further opportunities to support patients and their loved ones. We are grateful for their feedback and wish to thank them for their time.

Acute lymphocytic leukaemia panel

Prof. David Marks Prof. Adele Fielding Dr. Anthony Moorman Prof. Oliver Ottmann Dr. Nick Morley Dr. Sara Ghorashian Dr. Deborah Yallop Prof. Ajay Vora

Acute myeloid leukaemia panel

Dr. Manos Nikolousis Prof. Mary Frances McMullin Dr. Sahra Ali Dr. Steve Knapper Dr. Panagotis Kottaridis Prof. Rachael Hough (SCT adolescent leukaemia) Dr. David Taussig Dr. Priyanka Mehta (AML & CML Dr. Panagiotis Kottaridis Prof. Antonio Pagluica

Chronic lymphocytic leukaemia panel

Assoc. Prof. Anna Schuh Dr. Ben Kennedy Prof. Chris Fegan Prof. Guy Pratt Assoc. Prof Francesco Forconi Prof. Adrian Bloor, Dr. Shankara Paneesha, Dr. Alison McCaig,

Chronic myeloid leukaemia panel

Dr. Dragana Milojkovic Prof. Nick Cross Prof. Jane Apperley Prof. Stephen O’Brien Prof. Mhairi Copeland Prof. Adam Mead Dr Jonathan Kell Prof. George Follows Dr. Nilima Parry-Jones Dr. Piers Patten Dr. Chris Fox Dr. Renata Walewska Prof. Peter Hillmen Prof. John Gribben Dr Sunil Lyengar

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Other blood cancers panel

Prof. Claire Harrison (MPN) Dr. Claire Dearden (HCL) Dr. Sally Killick (MDS) Dr. Robert Marcus (Lymphoma) Simon Cheeseman (Pharmacist) Prof. Judith Marsh (Aplastic anaemia, MDS) Dr. Richard Kelly (Aplastic anaemia, MDS) Prof David Bowen (MDS) Dr Dima El-Shakari (LGLL, ALL, CLL)

GP advisory Panel

Dr. Rebecca Chellaswamy Dr. Ruth Corbally Dr. Elaine Hampton Dr. Tom Kneale Dr. Anish Kotecha Dr. Lily Lamb Dr. Rachael Marchant Dr. Richard Roope Dr. Lance Saker Dr Sarah Smith (Searle) Dr. Neil Smith Dr. Sarah Taylor Prof. David Weller

Nurse advisory panel

Sarah Blakey Sarah Watmough Jacqueline Stones Joanna Stokes Roxanne Spencer Alison Pugh Phyllis Paterson Lianne Palmer Aileen Nield Klara Matulay Laura Ledger Joanna Large Catherine Langton Catherine Kunatsa Helen Knight Caroline Kerr Michelle Kenyon Tracy Gunter Catherine Griffiths Kirsty Crozier Marife Colis

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Remuneration policy

Leukaemia Care is committed to paying our staff fairly and in a way to attract and retain the skills needed to deliver our vision and mission effectively.

When setting salaries for new roles or reviewing salaries for existing roles, we consider a range of factors. Leukaemia Care is committed to avoiding discrimination, including but not limited to the grounds of protected characteristics as set out in the Equality Act 2010.

When drafting this policy, Leukaemia Care was influenced by the National Council of Voluntary Organisation’s 2014 inquiry into executive pay (NCVO, Report of the Inquiry into Charity Senior Executive Pay and Guidance for Trustees on Setting Remuneration).

The Board of Trustees are responsible for setting renumeration levels for the senior management team. The CEO has the authority to agree salaries for all employees outside of the senior management team within the guidelines of this policy.

Leukaemia Care upholds a policy that the full-time equivalent ratio for remuneration between its highest paid member of staff and the median salary level will not exceed 3:1, and that remuneration will always meet all national pay standards, ensuring all staff are provided with a living wage.

Salaries are reviewed annually in February following annual appraisals and take effect from April. Staff are advised of any changes in writing stating the amount and the date from which it takes effect. A salary review does not imply an increase and in making any pay award the review will be based on the organisation’s financial health.

Leukaemia Care is committed to transparency in pay and publishes its salary banding on all job descriptions. Progression within a band is dependent on performance assessed at the annual appraisal. Change to a different band requires a significant change in job description reflective of the responsibilities of that band. All salary changes must be approved in advance by the CEO.

As part of our commitment to transparency, information regarding the salary bandings will be made available to all Leukaemia Care staff. The salary bands apply to all roles, unless identified as requiring specific professional qualifications that fall outside this banding. Identified roles may follow other scales, such as the NHS salary scale.

The remuneration policy is reviewed annually by Trustees. Salaries are reviewed annually in March/April following annual appraisals and take effect from the 1[st] day of the following month. Staff are advised of any changes in writing stating the amount and the date from which it takes effect. A salary review does not imply an increase and in making any pay award the review will be based on the organisation’s financial health. All fixed salary increases are capped within the bandings, one off discretionary payments and cost of living payments are not capped within the bandings.

Influenced by the 2014 NCVO inquiry referred to above, the Board of Trustees is committed to including the following information within its annual statutory report and financial statements:

Pensions

The charity will match employee contributions up to 7% of qualifying earnings to the government workplace scheme – NEST.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Volunteers

Our volunteers are key in assuring anyone affected by a leukaemia, MDS or MPN diagnosis receives the information and support they need. A big thank you to all our volunteers who got involved in 2022, this included patients, carers, healthcare professionals and members of the public.

In 2022 we appointed a Volunteer Coordinator; this is an employee who can support and celebrate our existing volunteers, build our volunteering program and strategy, handle the day-to-day administration of volunteering, and ensure a cohesive experience for volunteers across all roles.

Our Volunteer Coordinator implemented several new elements to improve the experience of our volunteers, including a volunteer handbook and a volunteer Facebook group to provide our volunteers with a place to communicate with each other, and will begin working towards the Investing in Volunteers standard in 2023.

In August 2022 we held a volunteer awards ceremony as part of our annual conference to celebrate the impact of our volunteers with staff nominating volunteers from different areas of the charity’s work.

Our aim is to continue to focus on creating a more cohesive experience for our volunteers. We plan to achieve the ‘Investing in Volunteers’ accreditation, to work closely with our volunteers to make sure that the experience is reflecting their needs, and to work to ensure that our volunteers reflect the diversity of the wider blood cancer community.

Our roles have grown in 2022, with the introduction of Area Ambassador volunteers. These are current patients who are happy to use their hospital visits to help us to ensure that our information is available in hospital waiting rooms and haematology clinics. The volunteers are onboarded and supported by our Volunteer Coordinator, who liaises with our Regional Coordinators on how each individual volunteer can make a difference in their hospital.

Our Buddy Support Service relies on patients and carers volunteering their time to support other patients and carers who may be struggling with their diagnosis or feeling isolated because of it. The volunteers are DBS checked, trained and provided with ongoing support by both our Volunteer Coordinator and our Buddy Coordinator, who is also a paid employee.

A huge amount of our information is distributed through our webinars, podcasts and online training events. These rely on patients and healthcare professionals to join us as speakers – providing attendees with relevant and up to date information not only on leukaemia, MDS and MPN but also tips on getting the most out of medical appointments, coping with fatigue, immunisations and the challenges of living with a compromised immune system among other topics.

Our healthcare professional volunteers are a vital resource across the charity, attending our medical advisory panels, reviewing our patient information, and attending policy events with us. We are extremely grateful to all these professionals, and the time they give. Included in this group are the many nurses who help to run our nationwide support groups ensuring patients do not become isolated because of their diagnosis. They are supported by our network of Regional Co-ordinators who provide practical, emotional, and administrative support to the group.

We also hold patient advisory panels made up of patients with a range of experiences of blood cancer and who are at a variety of stages of treatment, recovery or remission. These patients provide Leukaemia Care with vital feedback on our strategy and activities, ensuring our services remain relevant and timely. They also support with health technology appraisals, advice on advocacy requests from individual patients, content for articles, webinars and podcasts as well as reviewing patient information.

Our community fundraising volunteers place collection tins, hold supermarket collections, run events, and join the cheer squad for the London Marathon. As well as raising funds, they raise awareness of leukaemia and the support we provide within their local communities. 2022 has continued to hold challenges for these roles, with a delayed return to normal following the COVID-19 pandemic. Throughout we have had a core of community volunteers who have continued to do everything they can to help us to raise vital funds.

We also have several areas where people volunteer their time less formally, including the signing of petitions, sharing of information and, most importantly, sharing their story. Each year people share and record their leukaemia stories as part of '#SpotLeukaemia' to raise awareness of the signs and symptoms. We recognise that people connect with stories and the people at the heart of them and each year they help us spread the '#SpotLeukaemia' message a little wider. Going forwards we aim to bring these smaller volunteering efforts together into a section of “micro-volunteering” tasks, allowing our supporters to pick tasks that will fit easily into their day, taking up 10, 30 or 60 minutes depending on the task that they choose.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

In 2023 and beyond we have several new volunteer roles that we are hoping to introduce, including Facebook support group moderators, clinic stand volunteers and volunteer speakers. We are also looking at the possibilities of including volunteering in our corporate partnerships. At the centre of this we will always aim to focus on how these volunteers will further the key aims and objectives of the charity.

Some feedback from our volunteers:

“From the first moment I offered help the team have been super friendly and supportive and have made getting involved very easy. I have always felt useful, needed and part of the team.”

Feedback from Patient information reviewer and patient panellist

“I believe that patient input is crucial to achieving the most positive outcomes. I am a great advocate of support groups. I think that Leukaemia Care is a fantastic charity.”

Feedback from Patient Panellist

“I feel very supported, the team always respond to my emails etc, nothing is too much trouble, they never fob me off with my new ideas saying no can't do, they always give them a try and thankfully my ideas up to now have paid off.” Feedback from community fundraiser

“The training is well organised, and the ongoing support is amazing.” Feedback from Buddy

“It's very rewarding personally and hopefully you're contributing to help someone get through difficult times and the R&D to improve treatments and outcomes… You have a vibrant, friendly, and efficient team - it's a pleasure to work with you”

Feedback from Buddy & Cheer Squad member

Related parties

In addition to the trading subsidiary undertaking, Leukaemia Care Trading Limited, the only related parties are the Trustees and those individuals connected with them including family members, business associates and other charities in which they are involved. Please refer to note 12 in the financial statements for detail.

Auditor

In accordance with the company's articles, a resolution proposing that Kendall Wadley LLP be reappointed as auditor of the company will be put at a General Meeting.

Disclosure of information to auditor

Each of the trustees has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information.

The trustees' report was approved by the Board of Trustees.

Mr Christopher R G Matthews-Maxwell (Chair)

Trustee

21 June 2023

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

STATEMENT OF TRUSTEES' RESPONSIBILITIES FOR THE YEAR ENDED 31 DECEMBER 2022

The trustees, who are also the directors of Leukaemia Care for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the trustees are required to:

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable group and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charitable group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charitable group's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF LEUKAEMIA CARE

Opinion

We have audited the financial statements of Leukaemia Care (the ‘charitable group’) for the year ended 31 December 2022 which comprise the statements of financial activities, the balance sheets and the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable group’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF LEUKAEMIA CARE

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

Responsibilities of trustees

As explained more fully in the statement of trustees' responsibilities, the trustees, who are also the directors of the charitable group for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the trustees are responsible for assessing the charitable group’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable group or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities and fraud

Audit response to risks identified

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF LEUKAEMIA CARE

It should be noted that Auditing standards limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https:// www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charity’s trustees, as a body, in accordance with part 4 of the Charities (Accounts and Reports) Regulations 2008 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity’s trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Elizabeth Needham ACA CTA (VAT) (Senior Statutory Auditor) for and on behalf of Kendall Wadley LLP 21 June 2023 Chartered Accountants Statutory Auditor Granta Lodge 71 Graham Road Malvern Worcestershire WR14 2JS

Kendall Wadley LLP is eligible for appointment as auditor of the charitable group by virtue of its eligibility for appointment as auditor of a company under section 1212 of the Companies Act 2006.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2022

Unrestricted
Restricted
funds
funds
2022
2022
Notes
£
£
Income and endowments from:
Donations and
legacies
3
836,570
341,404
Trading income
4
193,750
-
Fundraising income
5
723,517
-
Investments
6
43,352
-
Other income
7
901
-
Total income
1,798,090
341,404
Expenditure on:
Raising funds
8
784,794
-
Charitable activities
9
937,681
257,067
Total expenditure
1,722,475
257,067
Net gains/(losses) on
investments
14
(77,221)
-
Net (outgoing)/incoming
resources
(1,606)
84,337
Other recognised gains and losses
Revaluation of
tangible fixed assets
12,640
-
Net movement in funds
11,034
84,337
Fund balances at 1 January
2022
2,960,454
71,581
Fund balances at 31
December 2022
2,971,488
155,918		 Total
Unrestricted
Restricted
funds
funds
2022
2021
2021
£
£
£
1,177,974
669,681
193,206
193,750
-
-
723,517
424,035
-
43,352
34,971
-
901
24,276
-
2,139,494
1,152,963
193,206
784,794
569,908
-
1,194,748
599,065
169,556
1,979,542
1,168,973
169,556
(77,221)
36,577
-
82,731
20,567
23,650
12,640
12,640
-
95,371
33,207
23,650
3,032,035
2,927,247
47,931
3,127,406
2,960,454
71,581		 Total
2021
£
862,887
-
424,035
34,971
24,276
1,346,169
569,908
768,621
1,338,529
36,577
44,217
12,640
56,857
2,975,178
3,032,035

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

STATEMENT OF FINANCIAL ACTIVITIES - CHARITY INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2022

Unrestricted
Restricted
funds
funds
2022
2022
Notes
£
£
Income and endowments from:
Donations and
legacies
3
836,570
341,404
Fundraising income
5
794,529
-
Investments
6
43,352
-
Other income
7
901
-
Total income
1,675,352
341,404
Expenditure on:
Raising funds
8
662,056
-
Charitable activities
9
937,681
257,067
Total expenditure
1,599,737
257,067
Net gains/(losses) on
investments
14
(77,221)
-
Net (outgoing)/incoming
resources
(1,606)
84,337
Other recognised gains and losses
Revaluation of
tangible fixed assets
12,640
-
Net movement in funds
11,034
84,337
Fund balances at 1 January
2022
2,960,454
71,581
Fund balances at 31
December 2022
2,971,488
155,918		 Total
Unrestricted
Restricted
funds
funds
2022
2021
2021
£
£
£
1,177,974
669,681
193,206
794,529
424,035
-
43,352
34,971
-
901
24,276
-
2,016,756
1,152,963
193,206
662,056
569,908
-
1,194,748
599,065
169,556
1,856,804
1,168,973
169,556
(77,221)
36,577
-
82,731
20,567
23,650
12,640
12,640
-
95,371
33,207
23,650
3,032,035
2,927,247
47,931
3,127,406
2,960,454
71,581		 Total
2021
£
862,887
424,035
34,971
24,276
1,346,169
569,908
768,621
1,338,529
36,577
44,217
12,640
56,857
2,975,178
3,032,035

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

CONSOLIDATED BALANCE SHEET

AS AT 31 DECEMBER 2022

Notes
Fixed assets
Tangible assets
16
Investments
17
Current assets
Stocks
19
Debtors falling due after one year
20
Debtors falling due within one year
20
Investments
21
Cash at bank and in hand
Creditors: amounts falling due within
one year
22
Net current assets
Total assets less current liabilities
Income funds
Restricted funds
24
Unrestricted funds
Designated funds
25
General unrestricted funds		 2022
£
£
879,550
611,708
1,491,258
35,404
-
407,042
403,520
961,507
1,807,473
(171,325)
1,636,148
3,127,406
155,918
1,347,823
1,623,665
2,971,488
3,127,406		 2021
£
£
870,617
685,554
1,556,171
-
103,000
313,735
402,060
734,703
1,553,498
(77,634)
1,475,864
3,032,035
71,581
1,087,127
1,873,327
2,960,454
3,032,035		 2021
£
£
870,617
685,554
1,556,171
-
103,000
313,735
402,060
734,703
1,553,498
(77,634)
1,475,864
3,032,035
71,581
1,087,127
1,873,327
2,960,454
3,032,035
1,556,171
1,475,864
3,032,035
71,581
2,960,454
3,032,035

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

CONSOLIDATED BALANCE SHEET (CONTINUED)

AS AT 31 DECEMBER 2022

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2022, although an audit has been carried out under section 144 of the Charities Act 2011.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements under the requirements of the Companies Act 2006, for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Trustees on 21 June 2023

Mr Christopher R G Matthews-Maxwell (Chair) Mrs W J Davies (Treasurer) Trustee Trustee

Company registration number 11911752

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

CHARITY BALANCE SHEET

AS AT 31 DECEMBER 2022

Notes
Fixed assets
Tangible assets
16
Investments
17
Current assets
Stocks
19
Debtors falling due after one year
20
Debtors falling due within one year
20
Investments
21
Cash at bank and in hand
Creditors: amounts falling due within
one year
22
Net current assets
Total assets less current liabilities
Income funds
Restricted funds
24
Unrestricted funds
Designated funds
25
General unrestricted funds		 2022
£
£
879,550
611,808
1,491,358
6,225
-
396,851
403,520
961,507
1,768,103
(132,055)
1,636,048
3,127,406
155,918
1,347,823
1,623,665
2,971,488
3,127,406		 2021
£
£
870,617
685,554
1,556,171
-
103,000
313,735
402,060
734,703
1,553,498
(77,634)
1,475,864
3,032,035
71,581
1,087,127
1,873,327
2,960,454
3,032,035		 2021
£
£
870,617
685,554
1,556,171
-
103,000
313,735
402,060
734,703
1,553,498
(77,634)
1,475,864
3,032,035
71,581
1,087,127
1,873,327
2,960,454
3,032,035
1,556,171
1,475,864
3,032,035
71,581
2,960,454
3,032,035

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

CHARITY BALANCE SHEET (CONTINUED)

AS AT 31 DECEMBER 2022

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2022, although an audit has been carried out under section 144 of the Charities Act 2011.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements under the requirements of the Companies Act 2006, for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Trustees on 21 June 2023

Mr Christopher R G Matthews-Maxwell (Chair) Mrs W J Davies (Treasurer) Trustee Trustee

Company registration number 11911752

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2022

Notes
Cash flows from operating activities
Cash generated from/(absorbed by)
operations
29
Investing activities
Purchase of tangible fixed assets
Purchase of investments
Proceeds from disposal of investments
Other investment movements
Investment income received
Net cash generated from/(used in)
investing activities
Net cash used in financing activities
Net increase/(decrease) in cash and cash
equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Relating to:
Cash at bank and in hand
Short term deposits included in current asset
investments		 2022
£
£
223,094
(32,034)
(69,247)
57,573
8,298
40,580
5,170
-
228,264
1,136,763
1,365,027
961,507
403,520		 2021
£
£
(96,832)
(12,364)
(485,914)
101,638
(12,473)
37,194
(371,919)
-
(468,751)
1,605,514
1,136,763
734,703
402,060

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

Charity information

Leukaemia Care is a private company limited by guarantee incorporated in England and Wales. The registered office is One Birch Court, Blackpole East, Worcester, WR3 8SG.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charitable group's [governing document], the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended), FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charitable group is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the charitable group. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2 Business combinations

In the parent company financial statements, the cost of a business combination is the fair value at the acquisition date of the assets given, equity instruments issued and liabilities incurred or assumed, plus costs directly attributable to the business combination.

1.3 Basis of consolidation

The consolidated group financial statements consist of the financial statements of the parent company Leukaemia Care together with all entities controlled by the parent company (its subsidiaries).

All financial statements are made up to 31 December 2022. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.

All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.

Subsidiaries are consolidated in the group’s financial statements from the date that control commences until the date that control ceases.

1.4 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charitable group has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.5 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

(Continued)

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charitable group.

1.6 Income

Income is recognised when the charitable group is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charitable group has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charitable group has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

1.7 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset’s use.

All expenditure is accounted for on an accruals basis, with the exception of expenditure directly attributable to forthcoming events. The income is recognised on receipt and so the expenditure is recognised at point of expense. Costs are allocated to a particular activity where the cost relates to that activity. Costs of generating funds comprise those costs directly attributable to raising funds through activities. Grants payable are recognised on an accruals basis. Salaries and central overhead costs are apportioned between costs of generating funds, charitable activities and governance costs based on estimate of staff time attributable to each.

1.8 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Freehold buildings Over 50 years Computers and other equipment over 3 or 4 years Fixtures and fittings over 10 years

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

(Continued)

Freehold land is not depreciated.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

The charity has no specific value above which it capitalises assets. Assets are capitalised when they are held for long term use.

1.9 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

1.10 Impairment of fixed assets

At each reporting end date, the charitable group reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.11 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition. Items held for distribution at no or nominal consideration are measured the lower of replacement cost and cost.

Net realisable value is the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.

1.12 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

1.13 Financial instruments

The charitable group has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charitable group's balance sheet when the charitable group becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost. Financial assets classified as receivable within one year are not amortised.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including creditors are initially recognised at transaction price. Financial liabilities classified as payable within one year are not amortised.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charitable group’s contractual obligations expire or are discharged or cancelled.

1.14 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the charitable group is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.15 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charitable group’s accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

As described above, the trustees annually exercise judgement through consideration of the carrying value of the freehold buildings held by the charity. Adjustments are made through the Statement of Financial Activities for changes in value determined by the review process.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

3 Donations and legacies Group and charity

Unrestricted
Restricted
funds
funds
2022
2022
£
£
Donations and gifts
229,046
122,951
Legacies receivable
366,506
45,318
Corporate grants and donations
241,018
173,135
836,570
341,404		 Total
Unrestricted
Restricted
funds
funds
2022
2021
2021
£
£
£
351,997
157,770
52,080
411,824
283,679
-
414,153
228,232
141,126
1,177,974
669,681
193,206		 Total
2021
£
209,850
283,679
369,358
862,887

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

4 Trading income
Group
Trading 2021
subsidiary
2022
£ £
Sales 193,750 -
5 Fundraising income
Group
**Unrestricted ** Unrestricted
funds funds
2022 2021
£ £
Fundraising events 723,517 424,035
Charity
**Unrestricted ** Unrestricted
funds funds
2022 2021
£ £
Fundraising events 794,529 424,035
6 Investments
Group and charity
**Unrestricted ** Unrestricted
funds funds
2022 2021
£ £
Rental income 25,900 25,900
Investment income 7,380 1,406
Interest receivable 10,072 7,665
43,352 34,971

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

7 Other income Group and charity

8 Unrestricted Unrestricted
funds
funds
2022
2021
£
£
Government Grants
-
23,082
Solar panels
901
1,194
901
24,276
The Government Grants were in relation to the Job Retention Scheme.
Raising funds
Group
Unrestricted Unrestricted
funds
funds
2022
2021
£
£
Fundraising and publicity
Staging fundraising events
198,534
309,000
Advertising
43,972
18,597
Other fundraising costs
73,022
33,876
Staff costs
284,286
173,573
Depreciation and impairment
4,564
2,139
Support costs
50,504
25,802
Fundraising and publicity
654,882
562,987
Trading costs
Other trading activities
79,330
-
Staff costs
43,408
-
Support costs
3,170
2,265
Trading costs
125,908
2,265
Investment management
4,004
4,656
784,794
569,908		 Unrestricted Unrestricted
funds
funds
2022
2021
£
£
Government Grants
-
23,082
Solar panels
901
1,194
901
24,276
The Government Grants were in relation to the Job Retention Scheme.
Raising funds
Group
Unrestricted Unrestricted
funds
funds
2022
2021
£
£
Fundraising and publicity
Staging fundraising events
198,534
309,000
Advertising
43,972
18,597
Other fundraising costs
73,022
33,876
Staff costs
284,286
173,573
Depreciation and impairment
4,564
2,139
Support costs
50,504
25,802
Fundraising and publicity
654,882
562,987
Trading costs
Other trading activities
79,330
-
Staff costs
43,408
-
Support costs
3,170
2,265
Trading costs
125,908
2,265
Investment management
4,004
4,656
784,794
569,908
562,987
-
-
2,265
2,265
4,656
569,908

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

8 Raising funds
(Continued)
Charity
Unrestricted Unrestricted
funds
funds
2022
2021
£
£
Fundraising and publicity
Staging fundraising events
198,534
309,000
Advertising
43,972
18,597
Other fundraising costs
73,022
33,876
Staff costs
284,286
173,573
Depreciation and impairment
4,564
2,139
Support costs
50,504
25,802
Fundraising and publicity
654,882
562,987
Trading costs
Support costs
3,170
2,265
Trading costs
3,170
2,265
Investment management
4,004
4,656
662,056
569,908		 Raising funds
(Continued)
Charity
Unrestricted Unrestricted
funds
funds
2022
2021
£
£
Fundraising and publicity
Staging fundraising events
198,534
309,000
Advertising
43,972
18,597
Other fundraising costs
73,022
33,876
Staff costs
284,286
173,573
Depreciation and impairment
4,564
2,139
Support costs
50,504
25,802
Fundraising and publicity
654,882
562,987
Trading costs
Support costs
3,170
2,265
Trading costs
3,170
2,265
Investment management
4,004
4,656
662,056
569,908
562,987
2,265
2,265
4,656
569,908

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

9 Charitable activities

Staff costs
Depreciation and impairment
Patient Services costs
Conferences
Help Line costs
Leukaemia Matters/Nursing Matters
Campaign costs
Other charitable activities
Nurse e-learning tool
GP's e-learning tool
Other grants
Database costs
Patient Advocacy
Website costs
Other costs
Share of support costs (see note 10)
Share of governance costs (see note 10)
Analysis by fund
Unrestricted funds
Restricted funds		 2022
£
700,036
31,177
63,588
2,256
7,109
28,378
42,683
18,913
(1,081)
5,384
168,054
5,482
(16,724)
22,578
2,842
1,080,675
106,677
7,396
1,194,748
937,681
257,067
1,194,748		 2021
£
504,029
27,250
35,692
2,102
4,109
11,172
15,425
15,317
512
2,400
50,000
4,469
3,709
13,669
-
689,855
73,481
5,285
768,621
599,065
169,556
768,621

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

10 Support costs Group and charity

Support costs
Group and charity
Staff costs
Office costs
Audit fees
Legal and professional
Trustee and meeting
expenses
Analysed between
Fundraising
Trading
Charitable activities		 Support
costs
Governance
costs
£
£
16,753
-
140,428
-
-
4,200
-
3,298
-
3,068
157,181
10,566
50,504
-
-
3,170
106,677
7,396
157,181
10,566		 2022
£
16,753
140,428
4,200
3,298
3,068
167,747
50,504
3,170
114,073
167,747		 Support
costs
Governance
costs
£
£
13,275
-
86,008
-
-
3,600
-
2,370
-
1,580
99,283
7,550
25,802
-
-
2,265
73,481
5,285
99,283
7,550		 2021
£
13,275
86,008
3,600
2,370
1,580
106,833
25,802
2,265
78,766
106,833

Governance costs includes payments to the auditors of £4,200 (2021- £3,600) for audit fees, In addition included in the costs of other trading activities is £3,500 (2021 - £nil) in respect of the audit of the financial statements of the subsidiary undertaking.

11 Auditor's remuneration

Fees payable to the charitable group's auditor and associates: 2022 2021
£ £
Audit of the charitable group's annual accounts 4,200 3,600

In addition £3,500 is payable in respect of the audit of the subsidiary undertaking.

12 Trustees

The charity reimburses expenses to Trustees and management committee members for travel, subsistence and telephone relating to charity business. The costs reimbursed to 2 (2021: 2) trustees for the current year were £2,521 (2021 : £670).

None of the trustees (or any persons connected with them) received any remuneration during the year.

The charity utilises the services of CKCA Limited to prepare the payroll, W Davies, trustee, is a director of this company. The services are provided on an arms length basis and the amount paid during the year amounted to £2,186 (2021: £1,916).

All trustees are covered by an indemnity insurance policy costing £819 (2021 : £611)

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

13 Employees

The average monthly number of employees during the year was:

Training and provision of care
Fundraising and publicity
Accounts and administration
Total
Employment costs
Wages and salaries
Social security costs
Other pension costs		 2022
Number
20
16
4
40
2022
£
930,750
78,226
35,507
1,044,483		 2021
Number
18
10
3
31
2021
£
615,806
47,835
27,236
690,877

The remuneration of key management personnel through payroll and other fees is £190,032 (2021:£158,284).

The number of employees whose annual remuneration was more than £60,000 is as follows:

The number of employees whose annual remuneration was
is as follows:		 more than £60,000
2022 2021
Number Number
£60,001 - £70,000 1 1
14 Net (losses)/gains on investments
Group and charity
Unrestricted Unrestricted
funds funds
2022 2021
£ £
Revaluation of investments (70,142) 15,328
Gain/(loss) on sale of investments (7,079) 21,249
(77,221) 36,577

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

15 Taxation

The charity is exempt from tax on income and gains falling within section 505 of the Taxes Act 1988 or section 252 of the Taxationof Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects.

The subsidiary undertaking is required to Gift Aid profits arising to the parent charity such that no tax charge arises.

16 Tangible fixed assets Group and charity

Cost
At 1 January 2022
Additions
At 31 December 2022
Depreciation and impairment
At 1 January 2022
Depreciation charged in the year
Revaluation
At 31 December 2022
Carrying amount
At 31 December 2022
At 31 December 2021		 Freehold
buildings
£
842,599
-
842,599
-
12,640
(12,640)
-
842,599
842,599		 Computers
and other
equipment
Fixtures and
fittings
£
£
244,639
14,656
32,034
-
276,673
14,656
220,358
10,919
21,635
1,466
-
-
241,993
12,385
34,680
2,271
24,281
3,737		 Total
£
1,101,894
32,034
1,133,928
231,277
35,741
(12,640)
254,378
879,550
870,617

The trustees consider that the value of the freehold property is not materially different from original cost and the computed depreciation charge for the year is accordingly reversed.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

17 Fixed asset investments

Group

Listed
investments
Cash in
portfolio
Other
investments
£
Cost or valuation
At 1 January 2022
663,937
21,617
-
Additions
69,247
(69,247)
-
Valuation changes
(70,142)
-
-
Other cash movements
859
2,516
-
Loss on disposal
(7,079)
-
-
Disposals
(57,573)
57,573
-
At 31 December 2022
599,249
12,459
-
Carrying amount
At 31 December 2022
599,249
12,459
-
At 31 December 2021
663,937
21,617
-
Charity
Listed
investments
Cash in
portfolio
Other
investments
£
Cost or valuation
At 1 January 2022
663,937
21,617
-
Additions
69,247
(69,247)
100
Valuation changes
(70,142)
-
-
Other cash movements
859
2,516
-
Loss on disposal
(7,079)
-
-
Disposals
(57,573)
57,573
-
At 31 December 2022
599,249
12,459
100
Carrying amount
At 31 December 2022
599,249
12,459
100
At 31 December 2021
663,937
21,617
-		 Total
£
685,554
-
(70,142)
3,375
(7,079)
-
611,708
611,708
685,554
Total
£
685,554
100
(70,142)
3,375
(7,079)
-
611,808
611,808
685,554

Other investments represents the interest in the subsidiary undertaking, see note 28.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

18 Financial instruments Group and charity

18
Financial instruments
Group and charity
Carrying amount of financial assets
Instruments measured at fair value through profit or loss
19
Stocks
Group
2022
£
Finished goods and goods for resale
35,404
20
Debtors
Group
2022
Amounts falling due within one year:
£
Trade debtors
183,372
Amounts owed by subsidiary undertakings
-
Other debtors
8,467
Prepayments and accrued income
215,203
407,042
Amounts falling due after more than one year:
2022
£
Prepayments and accrued income
-
Total debtors
407,042
21
Current asset investments
Group and charity
Unlisted investments		 Group
2021
£
-
Group
2021
£
48,208
-
99,626
165,901
313,735
2021
£
103,000
416,735		 2022
£
599,249
Charity
2022
£
6,225
Charity
2022
£
42,572
137,317
1,759
215,203
396,851
2022
£
-
396,851
2022
£
403,520		 2021
£
663,937
Charity
2021
£
-
Charity
2021
£
48,208
-
99,626
165,901
313,735
2021
£
103,000
416,735
2021
£
402,060

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

22 Creditors: amounts falling due within one year

Creditors: amounts falling due within one year
Other taxation and social security
Trade creditors
Accruals and deferred income		 Group
2022
£
24,912
66,584
79,829
171,325		 Group
2021
£
13,668
16,002
47,964
77,634		 Charity
2022
£
24,912
31,064
76,079
132,055		 Charity
2021
£
13,668
16,002
47,964
77,634

23 Retirement benefit schemes

Defined contribution schemes

The charitable group operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charitable group in an independently administered fund.

The charge to profit or loss in respect of defined contribution schemes was £35,507 (2021 - £27,236).

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

24 Restricted funds Group and charity

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

Movement in funds Movement in funds Movement in funds Movement in funds
Balance at 1 Incoming Resources Balance at Incoming Resources Balance at
January 2020 resources expended
1		 January 2022 resources expended 31 December
2022
£ £ £ £ £ £ £
The Lily Blaen Hope Fund 24,428 - (1,961) 22,467 - (13,083) 9,384
Information Booklets - 84,125 (60,538) 23,587 - (23,587) -
GP e-learning tool - 19,817 (12,261) 7,556 8,423 (15,979) -
Nurse Advisor - - - - 30,346 (30,346) -
Student/Education 5,000 - - 5,000 - - 5,000
Worcester Support Group 251 - (251) - - - -
Glasgow Area - 1,900 (1,900) - 1,900 (1,600) 300
KAy Kendall 93 - (93) - - - -
Support Group - Taunton 267 - (267) - - - -
Support Group - Scotland 6,472 - (1,962) 4,510 - (1,176) 3,334
Counselling Fund - 1,000 (1,000) - 10,005 (9,135) 870
Travel Grant - - (267) - 47,000 (47,000) -
Support Group - Glasgow and Aberdeen 2,000 - (454) 1,546 - 588 958
Support Group - South Shields 1,000 1,000 (1,962) 38 - (38) -
Support Group - Leicestershire 1,393 - - 1,393 - - 1,393
Patient Support - Worcestershire 1,900 - (1,900) - - - -
Birmingham Patient Conference 500 - - 500 - - 500
Welfare & Advocacy support 627 21,681 (22,308) - 11,594 (11,594) -
Belfast Hospital Support 2,000 - - 2,000 9,999 - 11,999
Bristol Hospital Support 2,000 - - 2,000 - (869) 1,131
Patient Conferences/Webinars - 7,000 (7,000) - 25,092 (25,092) -
Care Helpline Costs - 5,000 (4,016) 984 1,375 (2,359) -
Nurse e-learning - 10,183 (10,183) - 3,175 (3,175) -

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

24 Restricted funds

Restricted funds
Buddy Scheme
West Midlands Hospital Support
Digital Support
Support Group - Cambridge
Spot Leukaemia
Support Groups
Newcastle Hospital Support
UCHL Hospital Support
Manchester Hospital Support
Nottingham Hospital Support
Patient Support Scotland
William Davidson - Aberdeen Area
CAR-T
AML Information
AML Education
Yorkshire Patient Support
Wales Hospital Support
Support Group Wales		 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
47,931		 1,500
(1,500)
5,000
(5,000)
33,000
(33,000)
500
(500)
1,500
(1,500)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
193,206
(169,556)		 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
71,581		 (Continued)
19,243
(19,243)
-
9,500
(9,500)
-
-
-
-
-
-
-
14,654
(14,654)
-
5,851
(5,851)
-
1,000
-
1,000
2,000
(985)
1,015
7,000
(2,974)
4,026
9,454
-
9,454
5,000
(5,000)
-
45,318
(800)
44,518
20,000
(10,000)
10,000
15,000
-
15,000
23,135
-
23,135
10,000
(1,654)
8,346
3,965
-
3,965
1,375
(785)
590
341,404
(257,067)
155,918		 (Continued)
19,243
(19,243)
-
9,500
(9,500)
-
-
-
-
-
-
-
14,654
(14,654)
-
5,851
(5,851)
-
1,000
-
1,000
2,000
(985)
1,015
7,000
(2,974)
4,026
9,454
-
9,454
5,000
(5,000)
-
45,318
(800)
44,518
20,000
(10,000)
10,000
15,000
-
15,000
23,135
-
23,135
10,000
(1,654)
8,346
3,965
-
3,965
1,375
(785)
590
341,404
(257,067)
155,918
155,918

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

24 Restricted funds

(Continued)

The Lily Blaen Hope Fund: this represents a legacy that was received to be used for activities in Scotland.

Information booklets: funds received to assist in the production of information booklets.

GP e-learning tool: this represents income received specifically for the GP's e-learning tool.

Nurse Advisor - in support of the Nurse Advisor services.

Student/Education - to raise awareness.

Worcester Support Group - to facilitate activities for the group.

Glasgow Area - funds to support services in the Glasgow area.

Kay Kendall - grant towards non-staff costs of helpline services Support Group West Midlands - to facilitate activities for support groups in the area Support Group Durham - to facilitate activities for the group.

Support Group Taunton - to facilitate activities for the group.

Support Group Scotland - to facilitate activities for the groups in Scotland.

Counselling Fund - to support the activity of offering counselling to patients and family members affected by leukaemia

Travel Grant - to support people with the additional cost of travelling to hospital for treatment and monitoring appointments.

Support Group Glasgow & Aberdeen - to facilitate activities for support groups in these areas

Support Group South Shields - to facilitate activities for support groups in these areas Support Group Leicestershire - to facilitate activities for support groups in these areas

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

24 Restricted funds

(Continued)

Patient Support Worcestershire - to facilitate activities for support groups in this area Birmingham Patient Conference - to assist with the cost of patient conference in Birmingham Welfare & Advocacy Support - in support of advocacy and welfare advise Belfast Hospital Support - in support of the costs in providing ward support Bristol Hospital Support - in support of the costs in providing ward support Staffing Costs - to support the employment costs of the Welfare and Advocacy Officers Patient conferences/webinars - grants in support of conferences held in the year. Care Helpline costs: this represents income received specifically to meet the costs of the Care line. Support Groups - to facilitate activities for local support groups Nurse e-learning - funds to support the advancement of knowledge in the nursing profession. Buddy Scheme - one to one support for patients

West Midlands Hospital Support -to facilitate activities for local support groups Digital support - to support digital and information projects Support Group Cambridge - to facilitate activities for local support groups Spot Leukaemia - to raise awareness of signs and symptoms of Leukaemia CAR-T - offer grants and information to patients being treated with CAR-T. AML information - Providing a new suite of AML information.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

24 Restricted funds

(Continued)

AML Education - Education of Healthcare Practitioners and patients on AML testing.

Yorkshire Support - to facilitate activities and support in this area.

Wales Hospital Support - in support of costs in providing ward support.

Support Group Wales - to facilitate activities for support groups in this area.

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

25 Designated funds Group and charity

The income funds of the charity include the following designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes:

Balance at
1 January 2021
£
Fixed asset
fund
875,003
Strategic
implemen-
tation fund
459,100
1,334,103		 Movement in funds
Incoming
resources
Resources
expended
Transfers
Balance at
1 January 2022
£
£
£
£
-
-
(4,386)
870,617
252,116
(494,706)
-
216,510
252,116
(494,706)
(4,386)
1,087,127		 Transfers
Balance at
31 December
2022
£
£
8,934
879,551
251,762
468,272
260,696
1,347,823		 Transfers
Balance at
31 December
2022
£
£
8,934
879,551
251,762
468,272
260,696
1,347,823
1,347,823

Fixed assets fund: The Trustees have agreed to assign all tangible fixed assets held with the exception of any which have restrictions imposed upon them to a general fixed asset designated fund. This was done to ensure that the Charity will have suitable levels of reserves to meet future depreciation costs relating to these fixed assets and to recognise the fact that future depreciation charges will not directly affect the net operating capital of the Charity.

Strategic Implementation Fund: funds to support the implementation of the three year strategy adopted by the Trustees on 1 February 2023.

26 Analysis of net assets between funds Group and charity

Unrestricted
funds
Restricted
funds
2022
2022
£
£
Fund balances at 31
December 2022 are
represented by:
Tangible assets
879,550
-
Investments
611,708
-
Current assets/(liabilities)
1,480,230
155,918
2,971,488
155,918		 Total Unrestricted
funds
Restricted
funds
2022
2021
2021
£
£
£
879,550
870,617
-
611,708
685,554
-
1,636,148
1,404,283
71,581
3,127,406
2,960,454
71,581		 Total
2021
£
870,617
685,554
1,475,864
3,032,035

27 Related party transactions

The charity received £71,012 (2021 - £nil) from the subsidiary undertaking under a Gift Aid arrangement. There were no other disclosable related party transactions during the year (2021 - none).

DocuSign Envelope ID: 07F1E70D-FAE9-443B-8C1C-0B5AAB44E321

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

28 Subsidiaries

Details of the charitable group's subsidiaries at 31 December 2022 are as follows:

Name of undertaking
Registered		 Nature of business Class of % Held % Held
office shares held
**Direct **		 Indirect
Leukaemia Care Trading
England & Wales Fundraising		 Ordinary 100.00
Limited
29 Cash generated from operations 2022 2021
£ £
Surplus for the year 82,731 44,217
Adjustments for:
Investment income recognised in statement of financial activities (43,352) (34,971)
Loss/(gain) on disposal of investments 7,079 (21,249)
Fair value gains and losses on investments 70,142 (15,328)
Depreciation and impairment of tangible fixed assets 35,741 29,389
Movements in working capital:
(Increase) in stocks (35,404) -
Decrease/(increase) in debtors 12,466 (101,139)
Increase in creditors 93,691 2,249
Cash generated from/(absorbed by) operations 223,094 (96,832)

30 Analysis of changes in net funds

The charitable group had no debt during the year.